Contract with Customer, Liability, Noncurrent in USD of Ambrx Biopharma Cayman, Inc. from Q4 2019 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.
Summary
Ambrx Biopharma Cayman, Inc. quarterly Contract with Customer, Liability, Noncurrent history and change rate from Q4 2019 to Q2 2023.
  • Ambrx Biopharma Cayman, Inc. Contract with Customer, Liability, Noncurrent for the quarter ending 30 Jun 2023 was $1,749,000.000, a 58.8% decline year-over-year.
Contract with Customer, Liability, Noncurrent, Quarterly (USD)
Contract with Customer, Liability, Noncurrent, YoY Quarterly Change (%)

Ambrx Biopharma Cayman, Inc. Quarterly Contract with Customer, Liability, Noncurrent (USD)

Period Value YoY Chg Change % Date Report Filed
Q2 2023 $1,749,000 -$2,497,000 -58.8% 30 Jun 2023 10-Q 09 Aug 2023
Q1 2023 $1,749,000 31 Mar 2023 10-Q 11 May 2023
Q4 2022 $1,749,000 -$3,899,000 -69% 31 Dec 2022 10-Q 09 Aug 2023
Q2 2022 $4,246,000 30 Jun 2022 6-K 29 Aug 2022
Q4 2021 $5,648,000 -$4,083,000 -42% 31 Dec 2021 10-K 30 Mar 2023
Q4 2020 $9,731,000 -$1,280,000 -11.6% 31 Dec 2020 6-K 29 Aug 2022
Q4 2019 $11,011,000 31 Dec 2019 20-F 26 Apr 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.